Skip to main content

Table 1 Characteristics of the participants

From: Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study

Characteristic

TBQT-AFEB group (n = 132)

TBQT-ALEB group (n = 50)

LBQT group (n = 182)

Age (yrs), mean ± SD

47.1 ± 11.2

47.2 ± 12.1

48.09 ± 13.6

Male

52% (68/132)

52% (26/50)

47% (86/182)

Smoker

19% (25/132)

20% (10/50)

12% (21/182)

Drinker

20% (26/132)

20% (10/50)

26% (48/182)

BMI (kg/m2)

23.21 ± 2.96

22.70 ± 3.20

22.69 ± 3.54

Family history

22% (29/132)

22% (11/50)

19% (34/182)

Peptic ulcer disease

20% (27/132)

20% (10/50)

15% (28/182)

Chronic atrophic gastritis with intestinal metaplasia

36% (47/132)

36% (18/50)

39% (71/182)

Gastrointestinal symptoms

38% (50/132)

38% (19/50)

41% (75/182)

Clarithromycin resistance

57% (75/132)

56% (28/50)

59% (107/182)

  1. TBQT tailored, bismuth-based quadruple therapy, amoxicillin + levofloxacin or furazolidone + esomeprazole + colloidal bismuth pectin, LBQT levofloxacin- and bismuth-based quadruple therapy, amoxicillin + levofloxacin + esomeprazole + colloidal bismuth pectin, BMI body mass index